CNBX Pharmaceuticals Inc. (CNBX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
#3 BETHESDA METRO CENTER BETHESDA, MD 20814 |
| State of Incorp. | NV |
| Fiscal Year End | August 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 2/28/2025 MRQ | 11/30/2024 MRQ | 8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 17 | 26 | 130 | 118 | 1,386 | 778 | |||
| Cash and cash equivalent | 17 | 26 | 130 | 118 | 1,386 | 778 | |||
| Prepaid expense | 81 | 204 | 152 | ||||||
| Other undisclosed current assets | 5 | 5 | 95 | ||||||
| Total current assets: | 22 | 31 | 224 | 198 | 1,591 | 930 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 275 | 437 | 643 | 863 | |||||
| Other undisclosed noncurrent assets | 176 | 845 | 427 | ||||||
| Total noncurrent assets: | 275 | 613 | 1,488 | 1,289 | |||||
| TOTAL ASSETS: | 22 | 31 | 499 | 811 | 3,079 | 2,219 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 52 | 41 | 336 | 461 | 178 | 231 | |||
| Other undisclosed accounts payable and accrued liabilities | 52 | 41 | 336 | 461 | 178 | 231 | |||
| Debt | 1,328 | 1,295 | 1,344 | 1,759 | 872 | ||||
| Due to related parties | ✕ | ✕ | ✕ | ✕ | 224 | 224 | 224 | ||
| Other undisclosed current liabilities | 1,156 | 1,175 | 837 | ||||||
| Total current liabilities: | 2,537 | 2,511 | 2,516 | 2,443 | 1,273 | 455 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 2,537 | 2,511 | 2,516 | 2,443 | 1,273 | 455 | |||
| Equity | |||||||||
| Equity, attributable to parent | (2,514) | (2,480) | (2,017) | (1,632) | 1,806 | 1,765 | |||
| Common stock | 3 | 3 | 2 | 0 | 14 | 14 | |||
| Additional paid in capital | 22,471 | 22,471 | 22,240 | 18,032 | 17,063 | 15,372 | |||
| Accumulated other comprehensive loss | (2,575) | (1,906) | (2,774) | ||||||
| Accumulated deficit | (24,989) | (24,954) | (24,259) | (20,549) | (16,826) | (13,631) | |||
| Other additional capital | 3,460 | 3,460 | 2,784 | ||||||
| Total equity: | (2,514) | (2,480) | (2,017) | (1,632) | 1,806 | 1,765 | |||
| Other undisclosed liabilities and equity | 0 | ||||||||
| TOTAL LIABILITIES AND EQUITY: | 22 | 31 | 499 | 811 | 3,079 | 2,219 | |||
Income Statement (P&L) ($ in thousands)
| 2/28/2025 TTM | 11/30/2024 TTM | 8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 41 | 130 | 410 | 196 | 7 | |||
| Gain on disposition of assets for financial service operations | 196 | |||||||
| Cost of revenue (Other undisclosed Cost of revenue) | (6) | |||||||
| Gross profit: | 34 | 130 | 410 | 196 | 7 | |||
| Operating expenses | (430) | (713) | (1,342) | (2,954) | (2,600) | (3,051) | ||
| Other undisclosed operating income (loss) | 0 | (196) | 0 | |||||
| Operating loss: | (396) | (583) | (931) | (2,954) | (2,600) | (3,043) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 29 | (594) | (4,424) | |||||
| Interest and debt expense | (3) | (1) | (1) | (2) | (8) | |||
| Loss from continuing operations: | (370) | (583) | (933) | (2,955) | (3,197) | (7,476) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (2,955) | (3,197) | (7,476) | |
| Net loss: | (370) | (583) | (933) | (2,955) | (3,197) | (7,476) | ||
| Other undisclosed net income (loss) attributable to parent | (121) | (112) | (2,778) | (768) | 2 | 8 | ||
| Net loss available to common stockholders, diluted: | (490) | (695) | (3,710) | (3,723) | (3,194) | (7,467) | ||
Comprehensive Income ($ in thousands)
| 2/28/2025 TTM | 11/30/2024 TTM | 8/31/2024 | 8/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (370) | (583) | (933) | (2,955) | (3,197) | (7,476) | ||
| Other comprehensive income | 2,575 | |||||||
| Comprehensive income (loss): | (370) | (583) | 1,642 | (2,955) | (3,197) | (7,476) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (121) | (112) | (5,353) | (1,437) | 871 | (5,576) | ||
| Comprehensive loss, net of tax, attributable to parent: | (490) | (695) | (3,710) | (4,392) | (2,326) | (13,052) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.